vs
Healthpeak Properties（DOC）与West Pharmaceutical Services（WST）财务数据对比。点击上方公司名可切换其他公司
West Pharmaceutical Services的季度营收约是Healthpeak Properties的1.1倍（$805.0M vs $719.4M），Healthpeak Properties净利率更高（73.2% vs 16.4%，领先56.8%），West Pharmaceutical Services同比增速更快（7.5% vs 3.1%），Healthpeak Properties自由现金流更多（$357.0M vs $175.0M），过去两年Healthpeak Properties的营收复合增速更高（8.9% vs 7.6%）
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
美国West Pharmaceutical Services是注射用药品包装及给药系统的设计和制造商，1923年成立，总部位于宾夕法尼亚州埃克斯顿。成立初期主营注射类药物包装用橡胶组件，曾为青霉素和胰岛素生产商提供符合无菌要求的配套产品。
DOC vs WST — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $719.4M | $805.0M |
| 净利润 | $114.0M | $132.1M |
| 毛利率 | — | 37.8% |
| 营业利润率 | 17.4% | 19.5% |
| 净利率 | 73.2% | 16.4% |
| 营收同比 | 3.1% | 7.5% |
| 净利润同比 | 2406.4% | 1.5% |
| 每股收益（稀释后） | $0.16 | $1.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $719.4M | $805.0M | ||
| Q3 25 | $705.9M | $804.6M | ||
| Q2 25 | $694.3M | $766.5M | ||
| Q1 25 | $702.9M | $698.0M | ||
| Q4 24 | $698.0M | $748.8M | ||
| Q3 24 | $700.4M | $746.9M | ||
| Q2 24 | $695.5M | $702.1M | ||
| Q1 24 | $606.6M | $695.4M |
| Q4 25 | $114.0M | $132.1M | ||
| Q3 25 | $-117.1M | $140.0M | ||
| Q2 25 | $31.7M | $131.8M | ||
| Q1 25 | $42.8M | $89.8M | ||
| Q4 24 | $4.5M | $130.1M | ||
| Q3 24 | $85.9M | $136.0M | ||
| Q2 24 | $146.0M | $111.3M | ||
| Q1 24 | $6.7M | $115.3M |
| Q4 25 | — | 37.8% | ||
| Q3 25 | 58.6% | 36.6% | ||
| Q2 25 | 60.2% | 35.7% | ||
| Q1 25 | 61.1% | 33.2% | ||
| Q4 24 | 60.3% | 36.5% | ||
| Q3 24 | 60.0% | 35.4% | ||
| Q2 24 | 60.6% | 32.8% | ||
| Q1 24 | 59.8% | 33.1% |
| Q4 25 | 17.4% | 19.5% | ||
| Q3 25 | 9.2% | 20.8% | ||
| Q2 25 | 5.7% | 20.1% | ||
| Q1 25 | 7.7% | 15.3% | ||
| Q4 24 | -2.2% | 21.3% | ||
| Q3 24 | 14.1% | 21.6% | ||
| Q2 24 | 22.3% | 18.0% | ||
| Q1 24 | 3.7% | 17.7% |
| Q4 25 | 73.2% | 16.4% | ||
| Q3 25 | -16.6% | 17.4% | ||
| Q2 25 | 4.6% | 17.2% | ||
| Q1 25 | 6.1% | 12.9% | ||
| Q4 24 | 0.7% | 17.4% | ||
| Q3 24 | 12.3% | 18.2% | ||
| Q2 24 | 21.0% | 15.9% | ||
| Q1 24 | 1.1% | 16.6% |
| Q4 25 | $0.16 | $1.82 | ||
| Q3 25 | $-0.17 | $1.92 | ||
| Q2 25 | $0.05 | $1.82 | ||
| Q1 25 | $0.06 | $1.23 | ||
| Q4 24 | $0.02 | $1.78 | ||
| Q3 24 | $0.12 | $1.85 | ||
| Q2 24 | $0.21 | $1.51 | ||
| Q1 24 | $0.01 | $1.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $467.5M | $791.3M |
| 总债务越低越好 | $9.8B | $202.8M |
| 股东权益账面价值 | $7.5B | $3.2B |
| 总资产 | $20.3B | $4.3B |
| 负债/权益比越低杠杆越低 | 1.31× | 0.06× |
8季度趋势，按日历期对齐
| Q4 25 | $467.5M | $791.3M | ||
| Q3 25 | $91.0M | $628.5M | ||
| Q2 25 | $89.4M | $509.7M | ||
| Q1 25 | $70.6M | $404.2M | ||
| Q4 24 | $119.8M | $484.6M | ||
| Q3 24 | $180.4M | $490.9M | ||
| Q2 24 | $106.9M | $446.2M | ||
| Q1 24 | $101.8M | $601.8M |
| Q4 25 | $9.8B | $202.8M | ||
| Q3 25 | $9.1B | $202.7M | ||
| Q2 25 | $9.0B | $202.6M | ||
| Q1 25 | $8.9B | $202.6M | ||
| Q4 24 | $8.7B | $202.6M | ||
| Q3 24 | $8.6B | $202.6M | ||
| Q2 24 | $8.6B | $205.8M | ||
| Q1 24 | $8.8B | $206.2M |
| Q4 25 | $7.5B | $3.2B | ||
| Q3 25 | $7.6B | $3.1B | ||
| Q2 25 | $7.9B | $2.9B | ||
| Q1 25 | $8.2B | $2.7B | ||
| Q4 24 | $8.4B | $2.7B | ||
| Q3 24 | $8.6B | $2.8B | ||
| Q2 24 | $8.8B | $2.6B | ||
| Q1 24 | $8.9B | $2.7B |
| Q4 25 | $20.3B | $4.3B | ||
| Q3 25 | $19.6B | $4.1B | ||
| Q2 25 | $19.8B | $4.0B | ||
| Q1 25 | $19.8B | $3.6B | ||
| Q4 24 | $19.9B | $3.6B | ||
| Q3 24 | $20.0B | $3.7B | ||
| Q2 24 | $20.2B | $3.5B | ||
| Q1 24 | $20.5B | $3.6B |
| Q4 25 | 1.31× | 0.06× | ||
| Q3 25 | 1.20× | 0.07× | ||
| Q2 25 | 1.14× | 0.07× | ||
| Q1 25 | 1.08× | 0.08× | ||
| Q4 24 | 1.04× | 0.08× | ||
| Q3 24 | 1.00× | 0.07× | ||
| Q2 24 | 0.98× | 0.08× | ||
| Q1 24 | 0.99× | 0.08× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3B | $251.1M |
| 自由现金流经营现金流 - 资本支出 | $357.0M | $175.0M |
| 自由现金流率自由现金流/营收 | 49.6% | 21.7% |
| 资本支出强度资本支出/营收 | 124.4% | 9.5% |
| 现金转化率经营现金流/净利润 | 10.99× | 1.90× |
| 过去12个月自由现金流最近4个季度 | — | $468.9M |
8季度趋势，按日历期对齐
| Q4 25 | $1.3B | $251.1M | ||
| Q3 25 | $315.0M | $197.2M | ||
| Q2 25 | $363.5M | $177.1M | ||
| Q1 25 | $279.4M | $129.4M | ||
| Q4 24 | $1.1B | $190.1M | ||
| Q3 24 | $318.2M | $180.1M | ||
| Q2 24 | $316.2M | $165.0M | ||
| Q1 24 | $152.6M | $118.2M |
| Q4 25 | $357.0M | $175.0M | ||
| Q3 25 | — | $133.9M | ||
| Q2 25 | — | $101.9M | ||
| Q1 25 | — | $58.1M | ||
| Q4 24 | $333.7M | $85.2M | ||
| Q3 24 | — | $98.8M | ||
| Q2 24 | — | $64.8M | ||
| Q1 24 | — | $27.6M |
| Q4 25 | 49.6% | 21.7% | ||
| Q3 25 | — | 16.6% | ||
| Q2 25 | — | 13.3% | ||
| Q1 25 | — | 8.3% | ||
| Q4 24 | 47.8% | 11.4% | ||
| Q3 24 | — | 13.2% | ||
| Q2 24 | — | 9.2% | ||
| Q1 24 | — | 4.0% |
| Q4 25 | 124.4% | 9.5% | ||
| Q3 25 | — | 7.9% | ||
| Q2 25 | — | 9.8% | ||
| Q1 25 | — | 10.2% | ||
| Q4 24 | 105.6% | 14.0% | ||
| Q3 24 | — | 10.9% | ||
| Q2 24 | — | 14.3% | ||
| Q1 24 | — | 13.0% |
| Q4 25 | 10.99× | 1.90× | ||
| Q3 25 | — | 1.41× | ||
| Q2 25 | 11.48× | 1.34× | ||
| Q1 25 | 6.52× | 1.44× | ||
| Q4 24 | 235.43× | 1.46× | ||
| Q3 24 | 3.71× | 1.32× | ||
| Q2 24 | 2.17× | 1.48× | ||
| Q1 24 | 22.85× | 1.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOC
暂无分部数据
WST
| Proprietary Products | $661.8M | 82% |
| Contract Manufactured Products | $143.2M | 18% |
| Affiliated Entity | $3.3M | 0% |
